Differential Serum MicroRNA Profiling in Benign and Malignant Ovarian Tumours: An Exploratory Study Identifying hsa-miR-200c-3p as a Candidate Diagnostic Biomarker
Authors:
- Jose D. SantotoribioJSJose D. Santotoribio
- Juan Corral-PerezJuan Corral-Perez
- Laura Avila-Cabeza-De-VacaLALaura Avila-Cabeza-De-Vaca
- Manuel CostillaMCManuel Costilla
- María Mayor-ReyesMMMaría Mayor-Reyes
- Daniel Fatela-CantilloDFDaniel Fatela-Cantillo
- Jose M. SilvanJSJose M. Silvan
- Cristina CasalsCristina Casals
- Jesus G. Ponce-GonzalezJPJesus G. Ponce-Gonzalez
- Pablo Mesa-SuarezPMPablo Mesa-Suarez
- Carmen González MacíasCMCarmen González Macías
- Juan Jesús Fernández AlbaJAJuan Jesús Fernández Alba
Open Access
- 26 August 2026
- journal article
- research article
- Published by MDPI AG in Diagnostics
- Vol. 16 (17) , 2718
Abstract
Background/Objectives: Preoperative discrimination of benign from malignant adnexal masses remains a major clinical challenge, and circulating microRNAs (miRNAs) are candidate non-invasive biomarkers. This exploratory, hypothesis-generating study—not a diagnostic validation study—evaluated serum hsa-miR-200c-3p as a candidate diagnostic biomarker for ovarian malignancy. Methods: Serum from 39 women with an adnexal mass and a surgical indication (20 benign, 19 malignant), all with histological confirmation, was analysed. Of 179 assayed miRNAs, 178 were tested for differential expression (miR-103a-3p as endogenous reference) using the Mann–Whitney U test with Benjamini–Hochberg false-discovery-rate (FDR) correction; hsa-miR-200c-3p, a pre-specified miR-200 family candidate, was evaluated by ROC analysis and compared with, and adjusted for, CA 125, HE4 and age. Results: The malignant group was substantially older and more frequently postmenopausal. Thirty-eight miRNAs were significant after FDR correction; hsa-miR-200c-3p was up-regulated in malignancy. In the complete-case analysis restricted to the 35 participants with a detectable marker (20 benign, 15 malignant), the AUC was 0.893 (95% CI 0.76–0.99); however, four high-grade serous carcinomas showed undetectable serum hsa-miR-200c-3p, and when these were included and imputed as low expression (all-case analysis, n = 39) the AUC fell to 0.705 (95% CI 0.51–0.88). hsa-miR-200c-3p did not demonstrate statistically superior performance to HE4 (AUC 0.93) or CA 125 (0.89), with overlapping confidence intervals; any incremental value beyond established markers and age was modest and exploratory. Conclusions: Serum hsa-miR-200c-3p is a preliminary candidate that requires prospective, age-matched, adequately powered validation with pre-specified assays and analysis plans.Keywords
Funding Information
- Junta de Andalucía (PIP-0160-2022)
This publication has 29 references indexed in Scilit:
- Serum miR-200c-3p and miR-6134 as diagnostic biomarkers for epithelial ovarian cancerDiscover Oncology, 2025
- Identifying Serum Small Extracellular Vesicle MicroRNA as a Noninvasive Diagnostic and Prognostic Biomarker for Ovarian CancerACS Nano, 2023
- RefFinder: a web-based tool for comprehensively analyzing and identifying reference genesFunctional & Integrative Genomics, 2023
- Circulating cf-miRNA as a more appropriate surrogate liquid biopsy marker than cfDNA for ovarian cancerScientific Reports, 2023
- A novel circulating miRNA panel for non-invasive ovarian cancer diagnosis and prognosisBritish Journal of Cancer, 2022
- Cancer of the ovary, fallopian tube, and peritoneum: 2021 updateInternational Journal of Gynecology & Obstetrics, 2021
- Characterization of miR-200 family members as blood biomarkers for human and laying hen ovarian cancerScientific Reports, 2020
- MicroRNAs in ovarian cancer and recent advances in the development of microRNA-based biosensorsThe Analyst, 2020
- Prognostic significance of Dicer expression in ovarian cancer—link to global microRNA changes and oestrogen receptor expressionThe Journal of Pathology, 2009
- Bias reduction of maximum likelihood estimatesBiometrika, 1993